CAMP4 TherapeuticsCAMP.OValuation Analysis

As of Oct 16, 2026, CAMP4 Therapeutics (CAMP.O) trades at a negative P/E (-1.85x, due to a recent net loss), P/B of Negative, P/S of 47.20x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/S sits at the 16th percentile over the trailing 10Y window (vs. 16th percentile over 3Y).
Cross-sectional valuation: P/B percentile data for CAMP4 Therapeutics is still accumulating, both within its industry and across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. CAMP4 Therapeutics operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.